# Nanobody- and mini-G protein-enabled molecular pharmacology of HCAR1

> **NIH NIH R03** · STANFORD UNIVERSITY · 2023 · $154,625

## Abstract

Project Summary/Abstract
 Separate from its roles in cellular energy metabolism, the metabolite lactate influences multiple
physiological processes and contributes to cancer progression by acting as a signaling molecule. Cancer cells
often undergo metabolic reprogramming which results in increased lactate production and secretion.
Extracellular lactate activates hydroxycarboxylic acid receptor 1 (HCAR1), an understudied G protein-coupled
receptor that promotes tumor growth by driving cancer cell proliferation, stimulating tumor vascularization, and
inhibiting immune surveillance. Inhibiting HCAR1 activity represents a promising strategy for cancer treatment,
but the lack of selective pharmacological tools targeting HCAR1 hampers our ability to target this receptor in
disease and limits our understanding of HCAR1 function in physiology. Our long-term goal is to understand the
molecular basis for ligand recognition by HCAR1 and to use this information to design selective small molecules
targeting this receptor. This project will lay the foundation for future structure-based drug discovery efforts by
determining the ability of known HCAR1 ligands to promote binding between purified HCAR1 and engineered G
proteins (mini-G proteins) or camelid single-chain antibody fragments (nanobodies). In Aim 1, we will examine
the allosteric coupling between currently available HCAR1 agonists and a panel of mini-G proteins and
investigate the mechanism of action of potential HCAR1 antagonists. In Aim 2, we will identify conformationally
selective nanobodies that recognize HCAR1 and determine their selectivity and binding mode at HCAR1. In both
aims, we will determine conditions to form stable HCAR1 complexes for future structural studies of HCAR1 in
multiple states. This work will provide insight into the molecular pharmacology of currently available HCAR1
ligands, discover novel nanobodies to probe HCAR1 function, and enable future structure-based design of
HCAR1 ligands for cancer treatment.

## Key facts

- **NIH application ID:** 10666999
- **Project number:** 1R03TR004487-01
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** Theodore S Jardetzky
- **Activity code:** R03 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $154,625
- **Award type:** 1
- **Project period:** 2023-06-01 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10666999

## Citation

> US National Institutes of Health, RePORTER application 10666999, Nanobody- and mini-G protein-enabled molecular pharmacology of HCAR1 (1R03TR004487-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10666999. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*